Clinical Trials

Small Cell Lung Carcinoma

NCT03228043 2024-11-14

Apatinib for Resectable Colorectal Cancer

Phase NA Withdrawn

Phase 3 Not yet recruiting

Colorectal Neoplasms

NCT05019690 2024-09-19

Apatinib Combined with Albumin-Bound Paclitaxel for Treatment of Advanced Triple Negative Breast Cancer

Phase 1/2 Recruiting

29 enrolled

Breast

Advanced Triple Negative Breast Cancer

NCT06539091 2024-08-06

Fluzoparib in Combination With Apatinib Mesylate for Maintenance Therapy in Stage III-IV Ovarian Cancer

51 enrolled

Carcinoma, Ovarian Epithelial

NCT05597527 2022-10-28

Fluzopari Combined With Apatinib for the Neoadjuvant Treatment of Unresectable Ovarian Cancer

35 enrolled

Ovarian Neoplasms

NCT05380986 2022-05-19

Camrelizumab Combined With Apatinib Mesylate

Phase NA Unknown

500 enrolled

Other solid neoplasm

Solid Tumor

NCT04901754 2021-12-08

CAMERA

38 enrolled

Small Cell Lung Carcinoma

NCT04832204 2021-04-05

Apatinib Combined With SHR-1210 as Second-line Treatment in Solid Tumors With Only Liver Metastases

Other solid neoplasm

Solid Tumor

NCT03389087 2020-07-10

Study of Apatinib Plus Etoposide Capsule as the Therapy of Advanced Small Cell Lung Cancer

Small Cell Lung Carcinoma

NCT03397199 2020-04-15

Study of Apatinib Plus S-1 as the Therapy of Advanced Colorectal Cancer

120 enrolled

Colorectal Neoplasms

NCT04174339 2019-11-22

PD-1 Antibody(SHR-1210) Plus Apatinib Combined With POF in Advanced Gastric Cancer

Phase NA Unknown

Advanced Gastric Adenocarcinoma

NCT03986515 2019-06-14

Apatinib Plus SHR1210 in Advanced Mucosal Melanoma

40 enrolled

Dermatologic

Mucosal Melanoma

NCT03954756 2019-05-17

Exploratory Clinical Study of Apatinib and PD-1 in Treating Advanced Gastric Cancer

35 enrolled

Advanced Gastric Cancer

NCT03950141 2019-05-15

Apatinib Combined With S-1 as Maintenance Therapy for HER-2 Negatived Gastric Cancer

30 enrolled

HER-2 Negatived Gastric Cancer

NCT03942068 2019-05-08

Apatinib With Albumin-bound Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer

35 enrolled

Ovarian Neoplasms

NCT02697838 2018-10-17

Clinical Trial of Apatinib Reverses Chemotherapy-Resistance of Patients With Advanced Gastric Cancer

Stomach Neoplasms

NCT03599778 2018-07-26

XELOX Combined With Apatinib as Post-operative Chemotherapy in Locally Advanced Gastric Adenocarcinoma

Phase 1/2 Unknown

52 enrolled

Stomach Neoplasms

NCT03546855 2018-06-06

Apatinib Treating Patients With Advanced Cervical Cancer After Radiotherapy and First-line Chemotherapy.

69 enrolled

Uterine Cervical Neoplasms

NCT03547375 2018-06-06

Clinical Study of Apatinib in the Treatment of Advanced Ovarian Cancer After the Failure of Standard Chemotherapy

69 enrolled

Ovarian Neoplasms

NCT03424291 2018-02-06

A Retrospective Clinical Study of Apatinib in Combination With Radiotherapy / Chemotherapy Second-line and Above in the Treatment of Recurrent / Metastatic Head and Neck Squamous Cell Carcinoma

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT03383237 2017-12-27

Clinical Study of Apatinib as the Second-line Therapy in Malignant Melanoma

Dermatologic

Melanoma

NCT03334591 2017-11-14

Research On the Optimized Treatment Method For Apatinib's Cure Of Advanced Gastric Cancer

Two Different Treatment Methods

NCT03170310 2017-05-31

Apatinib Treatment for Advanced Esophagus Cancer

Advanced Esophagus Cancer

NCT03163381 2017-05-23

Apatinib Second Line Treatment for Advanced Osteosarcoma and Soft Tissue Sarcomas ,Openting ,Single Center, One-armed Clinical Study.

40 enrolled

Sarcoma

Osteosarcoma

NCT03030937 2017-01-25

Clinical Trial to Compare Apatinib Plus Irinotecan Versus Single Irinotecan as Second-line Treatment in AGC or EGJA

74 enrolled

Advanced Gastric Cancer Adenocarcinoma of Esophagogastric Junction

NCT02980809 2016-12-02

Topotecan Plus Apatinib Versus Topotecan Alone as Second-line Therapy in Small-cell Lung Cancer